SNTI Senti Biosciences, Inc.
Price Chart
Executive Summary
Senti Bio reported Q1 2026 EPS of -$0.14, beating consensus of -$0.36 by 61%, on minimal revenue of $16K. The beat is driven by a $6.9M non-recurring lease modification gain and reduced operating expenses. More importantly, the company secured a strategic financing vehicle for up to $40M (initial $10M tranche) and received positive FDA feedback supporting a single-arm pivotal trial for SENTI-202 in R/R AML, extending the cash runway and de-risking the regulatory path.
Actionable Insight
The combination of a strong EPS beat, reduced cash burn, and a $40M financing facility significantly de-risks the near-term dilution risk and extends runway through key SENTI-202 pivotal trial milestones. The positive FDA feedback on a single-arm pivotal trial is a major catalyst — watch for enrollment updates and potential partnership interest. The stock's small market cap ($30M) amplifies sensitivity to these binary pipeline events.
Key Facts
- Q1 2026 EPS -$0.14 vs consensus -$0.36 (beat by 61%)
- Net loss narrowed to $4.2M from $14.1M YoY, driven by $6.9M lease modification gain and lower R&D/G&A spend
- Cash and equivalents $8.9M as of March 31, 2026, down from $16.4M at year-end 2025
- Secured up to $40M strategic convertible note financing (initial $10M tranche expected to close May 2026)
- Positive FDA Type B RMAT meeting outcome supports single-arm pivotal trial design for SENTI-202 in R/R AML
- Identified Donor X attribute correlated with 50% composite CR rate in Phase 1; will be used in all future manufacturing
- Operating cash burn reduced to $7.5M in Q1 2026 vs $14.1M in Q1 2025
Financial Impact
EPS beat of 61% vs consensus; net loss improved by $9.9M YoY; cash runway extended by up to $40M financing
Risk Factors
- Cash burn continues; $8.9M cash on hand may require additional financing before the $40M facility is fully drawn
- SENTI-202 pivotal trial enrollment and results remain binary and uncertain
- Dilution risk from convertible note conversion if stock price appreciates
- Non-recurring lease modification gain ($6.9M) inflates reported net loss improvement
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294967 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
17d ago
|
8-K
| $1.01 $0.9750 | ▲ +3.47% | ▲ +3.93% | $0.9600 (+4.95%) |
|
May 14, 2026
29d ago
|
8-K
| $1.04 $0.9840 | ▼ −5.38% | ▼ −4.67% | $0.9600 (−7.69%) |
|
May 14, 2026
29d ago
|
Press Release
| $1.04 $0.9840 | ▼ −5.38% | ▼ −4.67% | $0.9600 (−7.69%) |
|
May 14, 2026
29d ago
|
Press Release
| $1.04 $0.9840 | ▼ −5.38% | ▼ −4.67% | $0.9600 (−7.69%) |
|
May 8, 2026
5w ago
|
15-12G
| $1.02 $0.9400 | ▼ −7.84% | ▼ −7.76% | $0.9600 (−5.88%) |
|
May 1, 2026
6w ago
|
424B5
| $0.9430 $1.02 | ▼ −8.17% | ▼ −5.23% | $0.9600 (−1.80%) |
|
Mar 27, 2026
11w ago
|
Press Release
| $0.7900 $0.9120 | ▲ +15.44% | ▲ +11.58% | $0.9600 (+21.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access